fbpx

molecules of the month

compound 57

oral EGFRL858R inhibitor

efficacy in EGFR mutant mouse models

SBDD opt. from previously disclosed EGFRai

J. Med. Chem.

F. Hoffmann-La Roche, Basel, CH

Compound 57 chemical structure oral EGFRL858R inhibitor - F. Hoffmann-La Roche, Basel, CH
5 mins read

Context. “Compound 57”  (Roche) is an oral allosteric EGFRL858R inhibitor being developed for NSCLC. Drug resistance and associated disease relapse continue to remain unmet needs for patients with NSCLC tumors harboring EGFR mutations, despite the availability of three generations of TKIs for EGFR+ NSCLC. Although the widely used third-generation agent osimertinib has been highly effective against the commonly occurring T790M mutation, the exon 19 deletion (ex19del), and the L858R sensitizing mutations, the drug has been largely inactive against the C797S-acquired mutation. Consequently, fourth-generation TKIs interact with an allosteric site generated by the L858R mutation, unlike current generation ATP-competitive agents. The newest class of inhibitors are actively been explored for treatment of L858R/C797-, L858R/T790M-, or L858R/T790M/C797S-mutant EGFR. We previously highlighted JBJ-09-063…


request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.


already a member? log in: